Steven R. Penegar
London, ENG, United Kingdom
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 15 publications
Outcomes of Intermediate Risk Non-muscle-invasive Bladder Cancer Receiving Adjuvant Treatment: A Pooled Analysis of Four Randomized Controlled Trials.
Journal: European urology oncology
Published: August 25, 2025
Letter: Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer: AUA/SUO Guideline: 2024 Amendment.
Journal: The Journal of urology
Published: February 07, 2025
Standardization of Radiation Therapy to Inguinal and Pelvic Lymph Nodes in Locally Advanced Cancer of the Penis, as Defined by the International Penile Advanced Cancer Trial (InPACT).
Journal: International journal of radiation oncology, biology, physics
Published: August 19, 2024
Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non-muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled Trial.
Journal: European urology open science
Published: May 12, 2023
Photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer: PHOTO RCT.
Journal: Health technology assessment (Winchester, England)
Published: October 27, 2022
A Randomized Trial of PHOTOdynamic Surgery in Non-Muscle-Invasive Bladder Cancer.
Journal: NEJM evidence
Published: October 01, 2022
CALIBER: a phase II randomized feasibility trial of chemoablation with mitomycin-C vs surgical management in low-risk non-muscle-invasive bladder cancer.
Journal: BJU international
Published: March 04, 2020
Photodynamic versus white light-guided treatment of non-muscle invasive bladder cancer: a study protocol for a randomised trial of clinical and cost-effectiveness.
Journal: BMJ open
Published: September 05, 2019
Association analyses identify 31 new risk loci for colorectal cancer susceptibility.
Journal: Nature communications
Published: October 31, 2018
Rare disruptive mutations and their contribution to the heritable risk of colorectal cancer.
Journal: Nature communications
Published: January 21, 2016
Genetic diagnosis of high-penetrance susceptibility for colorectal cancer (CRC) is achievable for a high proportion of familial CRC by exome sequencing.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: January 07, 2015
Last Updated: 09/26/2026